Publications

Filters (3)
March 18, 2021

Antimicrobial activity of the new FabI inhibitor Afabicin desphosphono against intraosteoblastic Staphylococcus aureus

Read more
August 3, 2020

Afabicin, a first-in-class anti-staphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical non-inferiority to vancomycin/linezolid

Read more
April 21, 2018

Staphylococcal-selective antibiotic afabicin preserves the human gut microbiota

Read more
October 29, 2016

The Staphylococcal-specific Antibiotic Debio 1450 Minimizes Disturbance to the Gut Microbiota in Mice

Read more
April 11, 2016

Activity of the novel Fabl inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid,…

Read more
September 19, 2015

Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and…

Read more
September 11, 2015

Safety, tolerability and pharmacokinetics of AFN–1252 administered as immediate release tablets in healthy subjects

Read more
April 27, 2015

Debiopharm group – strategically focused on narrow-spectrum antibiotics

Read more
May 13, 2014

Preclinical Pharmacokinetics and Efficacy of Debio 1450 (Previously AFN-1720), a Prodrug of the Staphylococcocal-specific Antibiotic Debio 1452 (Previously AFN-1252)

Read more